Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3LZ74 | ISIN: XS2842976289 | Ticker-Symbol:
Frankfurt
23.01.25
09:29 Uhr
99,93 Euro
+0,02
+0,02 %
Branche
Bau/Infrastruktur
Aktienmarkt
Anleihen
1-Jahres-Chart
ASSEMBLIN CAVERION GROUP AB Chart 1 Jahr
5-Tage-Chart
ASSEMBLIN CAVERION GROUP AB 5-Tage-Chart
PR Newswire
384 Leser
Artikel bewerten:
(2)

Caverion publishes certain key figures following the announcement of an offering of senior secured notes by Caverion's indirect parent company

Finanznachrichten News

Caverion Corporation Stock exchange release 10 June 2024 at 10:15 EET

HELSINKI, June 10, 2024 /PRNewswire/ -- Caverion publishes certain key figures following the announcement of an offering of senior secured notes by Caverion's indirect parent company

NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW.

Assemblin Caverion Group AB (publ), the indirect parent company of Caverion Corporation ("Caverion"), has today announced the offering of senior secured notes (the "Offering") and distributed a related offering memorandum in compliance with Rule 144A and Regulation S under the U.S. Securities Act of 1933, as amended, containing information concerning the Offering and the combined Assemblin Caverion Group, including certain financial and other information concerning the Caverion Group.

Caverion published by way of stock exchange release on 30 May 2024 unaudited condensed consolidated interim financial statements of the Caverion Group as of and for the three months ended 31 March 2024.

In addition, Caverion now announces certain supplementary operating data and Non-IFRS financial information, as set out in the below table in the form such is intended to be included in certain materials relating to the Offering. Further information regarding the Offering is available at the Assemblin Caverion Group website at https://www.assemblincaverion.com/investors.



For the year ended December 31,


For the three months
ended March 31,


As of and
for the
twelve
months
ended
March 31,




2021


2022


2023


2023


2024


2024




(EUR millions, unless otherwise indicated)


Caverion Order intake
...........


2,382.6


2,394.0


2,494.1


728.6


692.1


2,457.5


Caverion Order backlog
..........










2,032.7


2,032.7



Caverion Free Cash Flow is defined as Caverion Adjusted EBITDA, less non-lease tangible net capital expenditures, finance lease repayments (excluding interest) and change in Caverion Working Capital. Caverion Cash Conversion is defined as Caverion Free Cash Flow divided by Caverion Adjusted EBITA. The following is the calculated Caverion Free Cash Flow and Caverion Cash Conversion for the periods presented:



For the year ended December 31,


For the three months ended March 31,


For twelve
months
ended
March 31,




2021


2022


2023


2023


2024


2024




(EUR millions)


Caverion Adjusted EBITDA
.....


142.1


163.0


184.7


39.1


42.8


188.4


Non-lease tangible net capital expenditures


(4.4)


(5.6)


(6.8)


(1.9)


(2.1)


(6.9)


Finance lease repayments (excluding interest)


(46.9)


(49.8)


(52.9)


(12.3)


(13.5)


(54.2)


Change in Caverion Working Capital


(21.0)


9.4


14.0


10.6


(12.5)


(9.0)


Caverion Free Cash Flow
.......


69.7


117.0


138.9


35.4


14.7


118.2


Caverion Adjusted EBITA........


87.7


105.8


123.7


24.5


26.6


125.7


Caverion Cash Conversion (%)
..


79.5 %


110.6 %


112.3 %


144.8 %


55.4 %


94.1 %

















The key figures presented above constitute alternative performance measures that should be read together with Caverion's (interim) financial statements prepared in accordance with IFRS. Alternative performance measures are presented as they are believed to assist users of Caverion's (interim) financial statements in comparing performance across reporting periods. Alternative performance measures should not be considered in isolation or as a substitute for performance measures calculated in accordance with IFRS.

CAVERION CORPORATION

Distribution: Nasdaq Helsinki, key media, www.caverion.com

For further information, please contact:
Pasi Päivärinta, interim CFO, tel. +358 50 485 0304, pasi.paivarinta@caverion.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/caverion/r/caverion-publishes-certain-key-figures-following-the-announcement-of-an-offering-of-senior-secured-n,c3997710

The following files are available for download:

https://mb.cision.com/Main/14078/3997710/2853391.pdf

Release

Cision View original content:https://www.prnewswire.co.uk/news-releases/caverion-publishes-certain-key-figures-following-the-announcement-of-an-offering-of-senior-secured-notes-by-caverions-indirect-parent-company-302168126.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.